BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7415 related articles for article (PubMed ID: 24600975)

  • 21. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
    Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
    Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene.
    Watari K; Tojo A; Nagamura-Inoue T; Nagamura F; Takeshita A; Fukushima T; Motoji T; Tani K; Asano S
    FEBS Lett; 2000 Jan; 466(2-3):367-71. PubMed ID: 10682862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma.
    Ercolak V; Paydas S; Bagir E; Ergin M; Seydaoglu G; Celik H; Yavu B; Tanriverdi K; Gunaldi M; Afsar CU; Duman BB
    Acta Haematol; 2015; 134(4):199-207. PubMed ID: 26044287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
    Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
    Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML).
    Steger B; Floro L; Amberger DC; Kroell T; Tischer J; Kolb HJ; Schmetzer HM
    J Immunother; 2020; 43(6):204-215. PubMed ID: 32502139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
    Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
    Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
    Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
    Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo.
    Tajeddine N; Louis M; Vermylen C; Gala JL; Tombal B; Gailly P
    Leuk Lymphoma; 2008 Jun; 49(6):1123-31. PubMed ID: 18452107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies.
    Matsushita M; Yamazaki R; Ikeda H; Kawakami Y
    Leuk Lymphoma; 2003 Mar; 44(3):439-44. PubMed ID: 12688312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PRAME Gene Expression in Acute Leukemia and Its Clinical Significance.
    Ding K; Wang XM; Fu R; Ruan EB; Liu H; Shao ZH
    Cancer Biol Med; 2012 Mar; 9(1):73-6. PubMed ID: 23691459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Implication of MIF Gene Expression in Childhood Acute Lymphoblastic Leukemia.
    Sharaf-Eldein M; Elghannam D; Elderiny W; Abdel-Malak C
    Clin Lab; 2018 Sep; 64(9):1429-1437. PubMed ID: 30274020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of preferentially expressed antigen of melanoma (PRAME) gene expression with clinical characteristics in acute leukemia patients.
    Kulkarni NV; Shetty RA; Kumari N S; Shetty VV; Krishna R; Arumugam M; Kalal AA; Shetty P
    J Genet Eng Biotechnol; 2022 Jul; 20(1):97. PubMed ID: 35788450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PRAME Gene Copy Number Variation Is Related to Its Expression in Multiple Myeloma.
    Yang L; Wang YZ; Zhu HH; Chang Y; Li LD; Chen WM; Long LY; Zhang YH; Liu YR; Lu J; Qin YZ
    DNA Cell Biol; 2017 Dec; 36(12):1099-1107. PubMed ID: 28953414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PRAME expression in hairy cell leukemia.
    Arons E; Suntum T; Margulies I; Yuan C; Stetler-Stevenson M; Kreitman RJ
    Leuk Res; 2008 Sep; 32(9):1400-6. PubMed ID: 18295331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia.
    Steinbach D; Schramm A; Eggert A; Onda M; Dawczynski K; Rump A; Pastan I; Wittig S; Pfaffendorf N; Voigt A; Zintl F; Gruhn B
    Clin Cancer Res; 2006 Apr; 12(8):2434-41. PubMed ID: 16638849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes.
    Qin YZ; Zhu HH; Liu YR; Wang YZ; Shi HX; Lai YY; Xu LP; Liu DH; Jiang Q; Li LD; Jiang B; Liu KY; Huang XJ
    Leuk Lymphoma; 2013 Jul; 54(7):1442-9. PubMed ID: 23110703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
    Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
    JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo.
    Xu Y; Yue Q; Wei H; Pan G
    Int J Clin Exp Pathol; 2015; 8(11):14549-55. PubMed ID: 26823776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 371.